Research programme: microRNA therapeutics - Regulus Therapeutics

Drug Profile

Research programme: microRNA therapeutics - Regulus Therapeutics

Alternative Names: anti-miR-10b; anti-miR-122; miR-296; miR-34; miR-34a; miR-K12-11 (viral oncomir); miR-X; miRNA therapeutics - Regulus Therapeutics; Viral microRNAs - Regulus Therapeutics

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator California Institute of Technology/CalTech; Stanford University
  • Developer Cenix BioScience; Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; MicroRNA modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma; Hepatitis C; Non-alcoholic steatohepatitis
  • Discontinued Diabetes mellitus; Heart failure; Metabolic syndrome; Viral infections

Most Recent Events

  • 06 Jul 2018 Regulus Therapeutics expects to file an IND for the HBV program in second half of 2019
  • 26 Feb 2018 MicroRNA therapeutics are still in preclinical trials for Hepatitis C in USA (Regulus Therapeutics pipeline, February 2018)
  • 26 Feb 2018 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route) (Regulus Therapeutics pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top